louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00739180: Physical Activity in Youth: Implications for Reversing Risk Factors for Type 2 Diabetes
Official title: Physical Activity in Youth: Implications for Reversing Risk Factors for Type 2 Diabetes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Abdominal Obesity
Keywords: Childhood obesity
Abdominal obesity
Visceral fat
Insulin resistance
Liver fat
Skeletal muscle lipid
Fitness
Lead sponsor: University of Pittsburgh
Sponsor class: OTHER
Collaborators: name: American Diabetes Association
First posted: 2008-08-21
Enrollment: 45
Sex: MALE
Minimum age (years): 12
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: In this randomized controlled trial, we will examine the effect of a 3-month exercise training (aerobic exercise versus resistance exercise) without calorie restriction on total and regional adiposity, and risk of type 2 diabetes in overweight children and adolescents.


Eligibility criteria: Inclusion Criteria:

* Healthy overweight (BMI \>-95th) youth between 12 and 18 years of age
* Waist circumference \>-75th percentile
* Sedentary (no structured exercise \>2 times/week for past 6 months)
* Non-smokers, non-diabetic, no medical conditions
* Weight stable for past 3 months

Exclusion Criteria:

* Smokers,
* diabetic,
* psychiatric disorders,
* syndromatic obesity

Primary outcomes:
measure: Abdominal obesity, visceral fat
timeFrame: 3 month
Secondary outcomes:
measure: Insulin sensitivity and secretion, glucose tolerance
timeFrame: 3 month
Other outcomes:
Locations:
city: Pittsburgh
country: United States
facility: Children's Hospital of Pittsburgh, University of Pittsburgh School of Medicine
state: Pennsylvania
Study officials:
affiliation: University of Pittsburgh
name: SoJung Lee, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Yu WW, Lee S, Arslanian S, Tamim H, Kuk JL. Effects of Exercise on Resting Metabolic Rate in Adolescents with Overweight and Obesity. Child Obes. 2021 Jun;17(4):249-256. doi: 10.1089/chi.2020.0280. Epub 2021 Mar 18.
citation: Kuk JL, Lee S. Assessing the utility of cardiorespiratory fitness, visceral fat, and liver fat in predicting changes in insulin sensitivity beyond simple changes in body weight after exercise training in adolescents. Appl Physiol Nutr Metab. 2021 Jan;46(1):55-62. doi: 10.1139/apnm-2020-0284. Epub 2020 Jul 16.
citation: Kuk JL, Lee S. Sex and Ethnic Differences in the Relationship between Changes in Anthropometric Measurements and Visceral Fat in Adolescents with Obesity. J Pediatr. 2019 Oct;213:121-127. doi: 10.1016/j.jpeds.2019.05.052. Epub 2019 Jun 22.
Clinical trial NCT01485380: Combined Electroencephalogram, Magnetic Resonance Imaging-Positron Emission Tomography of Dexmedetomidine Induced Sleep
Official title: Combined Electroencephalogram, Magnetic Resonance Imaging-Positron Emission Tomography of Dexmedetomidine Induced Sleep
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dexmedetomidine Induced Sedation
Keywords: Dexmedetomidine
Sleep
MRI-PET
EEG
Lead sponsor: Massachusetts General Hospital
Sponsor class: OTHER
First posted: 2011-12-05
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: The investigators are doing this research study to find out how and where dexmedetomidine, a sedative anesthetic, acts in the brain. The investigators will do this by using a machine that records the brains electrical activity, called an electroencephalogram (EEG), and brain imaging scans to look at the brain.


Eligibility criteria: Inclusion Criteria:

* American Society of Anesthesiologists (ASA) physical status I
* 18 to 35 years of age

Exclusion Criteria:

* MRI and/or PET screening criteria not met
* Abnormal sleep habits/known or suspected sleep disorder(s)
* Taking medication that alters sleep, cognitive function, or both -History of a known neurological or psychiatric problem -Younger than 18 or older than 35 years of age

Primary outcomes:
measure: Number of Participants With Changes in the Brains Default Mode Network.
timeFrame: 1.5hrs
Secondary outcomes:
Other outcomes:
Locations:
city: Boston
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
Study officials:
affiliation: Massachusetts General Hospital
name: Oluwaseun Johnson-Akeju, M.D
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06986980: Intestinal Microsporidiosis in French Heart Transplant Recipients (CARMIC)
Official title: Intestinal Microsporidiosis in French Heart Transplant Recipients
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Microsporidiosis Intestinal
Heart Transplant Infection
Keywords: microsporidiosis
Enterocytozoon bieneusi
Encephalitozoon intestinalis
Encephalitozoon hellem
solid organ transplant
heart transplant
Lead sponsor: University Hospital, Clermont-Ferrand
Sponsor class: OTHER
First posted: 2025-05-23
Enrollment: 39
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Heart transplant patients with microsporidiosis

Brief summary: The investigators propose to carry out a national retrospective study to collect epidemiological, biological, clinical and therapeutic data on microsporidiosis among heart transplant patients.

Detailed description: Microsporidia constitute a large family of intracellular eukaryotes infecting a wide range of hosts, ranging from insects to mammals and birds. Within this group, some species are responsible for intestinal syndromes manifested by abundant watery diarrhea, which can be particularly severe in immunocompromised individuals. In the 1980s, HIV-positive patients at the AIDS stage represented the primary population at risk. Nowadays, the most frequently affected patients among immunocompromised individuals are solid organ transplant recipients, for whom the management of this infection can be challenging. A neglected pathology until a few years ago, epidemiological data describing intestinal microsporidiosis in solid organ transplant recipients are scarce. The invesigators previously published the first data in kidney and liver transplant recipients. Here the investigators propose to carry out a national retrospective study to collect epidemiological, biological, clinical and therapeutic data on heart transplant patients.

Eligibility criteria: Inclusion Criteria:

* heart transplant patients diagnosed with intestinal microsporidiosis
* diagnosis made before December 31, 2024 in France (metropolitan France and overseas territories)

Exclusion Criteria:

-patient opposition

Primary outcomes:
measure: Demographic data: age
timeFrame: 1 year
measure: Demographic data: sex
timeFrame: 1 year
measure: Time between transplant and microsporidiosis
timeFrame: 1 year
measure: At diagnosis: number of days since the onset of symptoms
timeFrame: 1 year
measure: Weight loss at diagnosis
timeFrame: 1 year
measure: Dosage of immunosuppressants at diagnosis
timeFrame: 1 year
measure: Time to stool negativation
timeFrame: 1 year
measure: Creatinine level in blood at Day 0 (diagnosis) and Month 3
timeFrame: 3 months
measure: Numeration of cells in blood: platelets, lymphocytes, neutrophils at Day 0 (diagnosis) and Month 3
timeFrame: 3 months
measure: Gammaglobulins in blood at diagnosis
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05512780: Dalpiciclib Combined With Letrozole in Neoadjuvant Treatment of Stage Ⅱ-Ⅲ HR-positive/HER2-negative Breast Cancer
Official title: An Exploratory Clinical Study of CDK4/6 Inhibitor Dalpiciclib Combined With Letrozole in Neoadjuvant Treatment of Stage Ⅱ-Ⅲ HR-positive/HER2-negative Breast Cancer
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Solid Tumor
Lead sponsor: Hebei Medical University Fourth Hospital
Sponsor class: OTHER
First posted: 2022-08-23
Enrollment: 30
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a single-arm, open-label, exploratory clinical study

Detailed description: This is a single-arm, open-label, exploratory clinical study initiated by the investigator to evaluate the objective response rate (ORR), efficacy, and safety of Dalpiciclib combined with letrozole in the neoadjuvant treatment of stage Ⅱ-Ⅲ HR+/HER2- breast cancer.

Eligibility criteria: Inclusion Criteria:

* 1. Postmenopausal women aged ≥18 years, the definition of postmenopausal:

  1. the patients with the history of bilateral oophorectomy, or age ≥ 60 years; or
  2. Age \<60, natural postmenopausal state (defined as the spontaneous cessation of regular menstruation for at least 12 consecutive months, without other pathological or physiological causes), E2 and FSH at the postmenopausal levels 2. All patients were estrogen receptor (ER) positive (\>10%), HER2 -negative invasive breast cancer regardless of PR expression level. Immunohistochemistry (IHC) score of 0+, or 2+ confirmed by pathology laboratory and negative in situ hybridization (ISH) test (HER-2/CEP17 ratio \<2.0); 3. Treatment-naive patients with stage Ⅱ-Ⅲ tumors whose tumor staging meets the criteria of the 8th edition of the American Joint Committee on Cancer (AJCC) Staging;

Exclusion Criteria:

* 1. Received any form of anti-tumor therapy (chemotherapy, radiotherapy, molecular targeted therapy, endocrine therapy, etc.) 2. Concurrently receiving any other anti-tumor therapy that those specified in the protocol; 3. Bilateral breast cancer, inflammatory breast cancer, or occult breast cancer; 4. Stage Ⅳ breast cancer;

Primary outcomes:
measure: ORR
timeFrame: 24 month
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04505280: Greater Occipital Nerve and Cervical Region Injection in Patients With Trigeminal Neuralgia
Official title: Greater Occipital Nerve and Cervical Region Injection in Patients With Trigeminal Neuralgia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Trigeminal Neuralgia
Keywords: Trigeminal Neuralgia
Greater Occipital Nerve Block
Lidocaine
Lead sponsor: Dr. Lutfi Kirdar Kartal Training and Research Hospital
Sponsor class: OTHER_GOV
First posted: 2020-08-10
Enrollment: 29
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The aim of this study is to investigate the efficacy of greater occipital nerve block and cervical injections with lidocaine

Detailed description: After being informed about the study and potantiel risks, all patients giving informed consent will undergo randomization in 1:1 ratio to 1% lidocaine or 0.9% saline groups

Eligibility criteria: Inclusion Criteria:

* Classical Trigeminal Neuralgia

Exclusion Criteria:

* Secondary Trigeminal Neuralgia

Primary outcomes:
measure: Efficacy on pain severity
timeFrame: 3 months
measure: Efficacy on pain frequency
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Afyonkarahisar
country: Turkey
facility: Afyonkarahisar University of Health Sciences
state: Kartal/Soğanlık
Study officials:
References:
Clinical trial NCT01317680: Low Intensity Shock Wave Therapy (LI-ESWT) for Erectile Dysfunction in Post Radical Prostatectomy Patients Not Responding to PDE5 Inhibitors (LI-ESWT)
Official title: Low Intensity Shock Wave Therapy for Erectile Dysfunction in Post Radical Prostatectomy Patients Not Responding to PDE5 Inhibitors- a Double Blind Placebo Controlled Study (LI-ESWT)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Erectile Dysfunction
Keywords: Erectile Dysfunction
ED
PDE5 inhibitors
LI-ESWT
Lead sponsor: Rambam Health Care Campus
Sponsor class: OTHER
First posted: 2011-03-17
Enrollment: 60
Sex: MALE
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Low intensity shock waves (LISW) have been proven in animal studies to induce local growth of new blood vessels. The investigators hypothesized that LISW therapy could improve the symptoms of patients with erectile dysfunction resulting from a problem of blood supply (damage that can occur after radical prostatectomy in addition to neural damage or solely) that do not respond to oral therapy (PDE-5 inhibitors).


Eligibility criteria: Inclusion Criteria:

* Prior prostatectomy surgery
* ED of more than 6 months
* Rigidity score \< 3 during PDE5i therapy
* Non- hormonal, neurological or psychological pathology Stable heterosexual relationship for more than 3 months

Exclusion Criteria:

* Any unstable medical, psychiatric, spinal cord injury and penile anatomical abnormalities
* Clinically significant chronic hematological disease
* Anti-androgens, oral or injectable androgens
* Radiotherapy in pelvic region

Primary outcomes:
measure: Increase in IIEF ED Domain Questionaire of >5 is considered as a treatment success
timeFrame: 3 months
Secondary outcomes:
measure: Rigidity Score Questionaire- an increase of at least 1 point is considered as a treatment success
timeFrame: 3 months
Other outcomes:
Locations:
city: Haifa
country: Israel
facility: Rambam Medical Center
Study officials:
References:
Clinical trial NCT00602680: Effect on Cognitive Performance and Safety/Tolerability of SSR180711C in Mild Alzheimer's Disease
Official title: A Multicenter, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance and Safety/Tolerability of SSR180711C for 4 Weeks, Using Donepezil as Calibrator, in Patients With Mild Alzheimer's Disease
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Alzheimer's Disease
Keywords: Alzheimer
cognitive
Lead sponsor: Sanofi
Sponsor class: INDUSTRY
First posted: 2008-01-28
Enrollment: 1
Sex: ALL
Minimum age (years): 55
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The primary objective of the study is to assess the effect of 3 doses of SSR180711C on cognitive performance in patients with mild Alzheimer's Disease (AD). Other objectives are to assess the safety/tolerability of SSR180711C in patients with mild AD.


Eligibility criteria: Inclusion Criteria:

* Outpatients with diagnosis of mild AD

Exclusion Criteria:

* Concomitant or previous treatment by acetylcholinesterase inhibitors and/or memantine
* Medical condition which may interfere with the study
* History of epileptic seizures
* Lens opacity
* Lack of reliable caregiver

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Primary outcomes:
measure: Change in cognitive performance
timeFrame: 4 weeks
Secondary outcomes:
measure: Cognitive, global, functional and behaviorial assessments
timeFrame: 4 weeks
Other outcomes:
Locations:
city: Paris
country: France
facility: Sanofi-Aventis Administrative Office
Study officials:
affiliation: Scientific Advisory Committee
name: Bruno DUBOIS, MD
role: STUDY_CHAIR
References:
Clinical trial NCT00993980: Qigong and Exercise Therapy for Low Back Pain in Adults
Official title: Randomized Multicenter Trial on the Effectiveness of Qigong and a Stabilizing Exercise Therapy in Patients With Low Back Pain
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Low Back Pain
Keywords: qigong
traditional chinese medicine
exercise therapy
low back pain
Lead sponsor: Charite University, Berlin, Germany
Sponsor class: OTHER
First posted: 2009-10-14
Enrollment: 127
Sex: ALL
Minimum age (years): 20
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to assess the effectiveness of qigong for the treatment of low back pain compared to a stabilizing exercise therapy.


Eligibility criteria: Inclusion Criteria:

* clinical diagnosis of chronic low back pain since at least 3 months and complaints for a maximum duration of 5 years
* low back pain more prominent than other pain in the spine
* average pain intensity of the last 7 days more or equal to 40 mm measured by a visual analogue scale (VAS 0 - 100 mm)
* intellectual and physical ability to participate in the study
* informed consent

Exclusion Criteria:

* low back pain related to malignancy
* low back pain due to an accident
* inflammatory joint disorders
* previous spine surgery
* protrusion/prolapse of a spinal disk, spondylolisthesis, with radicular symptomatology
* actually doing or planning to do other regular physical exercise during the study with possible positive effects on low back pain - such as swimming, yoga, pilates, tai chi, etc.
* planning to do another therapy during the study with possible positive effects in low back pain, such as physiotherapy, acupuncture, massage, spinal manipulation etc.
* use of pain drugs for other diseases (\> 1x/week)
* pregnancy
* severe chronic or acute disease interfering with therapy attendance
* alcohol or substance abuse
* participation in another clinical trial in the last 6 months before study entry

Primary outcomes:
measure: average pain intensity during the last 7 days measured on a visual analogue scale (VAS)
timeFrame: baseline, 3, 6 and 12 months
Secondary outcomes:
measure: disability (Roland-Morris-Questionnaire RMQ)
timeFrame: baseline, 3, 6 and 12 months
measure: health related quality of life (SF 36)
timeFrame: baseline, 3, 6 and 12 months
measure: credibility of the therapy for patients
timeFrame: baseline, 3, 6 and 12 months
measure: patient expectation and self efficacy
timeFrame: baseline, 3, 6 and 12 months
measure: therapist's expectation
timeFrame: baseline, 3, 6 and 12 months
measure: sleep quality
timeFrame: baseline, 3, 6 and 12 months
measure: undesired effects
timeFrame: baseline, 3, 6 and 12 months
Other outcomes:
Locations:
city: Berlin
country: Germany
facility: Institute for Social Medicine, Epidemiology, and Health Economics, Charité University Medical Center
Study officials:
affiliation: Charite University, Berlin, Germany
name: Claudia M Witt, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02646280: Myofascial Massage in the Treatment of Chronic Low Back Pain
Official title: The Myofascial Massage in the Treatment of Chronic Non-specific Low Back Pain: the Experience of Contact
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Chronic Low Back Pain
Keywords: Low back pain
interoceptive awareness
motor imagery
massage
Lead sponsor: University of Roma La Sapienza
Sponsor class: OTHER
First posted: 2016-01-05
Enrollment: 51
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to determine the effectiveness of an approach that combines massage therapy with elements of neurocognitive rehabilitation such as motor imagery and the words of the physiotherapist compared to a traditional massage therapy in reducing pain in patients with chronic low back pain (CLBP) and to evaluate if and how the pain reduction is linked to the interoceptive awareness and which is the patient's ability to relax through the measurement of the hearth rate variability (HRV).


Eligibility criteria: Inclusion Criteria:

* Presence of chronic nonspecific low back pain for at least three months
* Subjects aged between 18 and 50 years

Exclusion Criteria:

* Presence of acute low back pain
* Low back pain due to other causes (vertebral fractures, spondylolisthesis, herniated discs, lumbar canal stenosis)
* Disorders of central and/or peripheral nervous system
* Systemic inflammatory disease (eg rheumatoid arthritis)
* Systemic infectious disease
* Neoplastic disease
* Previous Surgery
* Cognitive impairment
* Pregnancy

Primary outcomes:
measure: Change of Visual Analogue Scale (VAS) from baseline to 12 weeks
timeFrame: baseline, 4 weeks, 12 weeks
Secondary outcomes:
measure: Change of McGill Pain Questionnaire from baseline to 12 weeks
timeFrame: baseline, 4 weeks, 12 weeks
measure: Change of Multidimensional Assessment of Interoceptive Awareness (MAIA) from baseline to 12 weeks
timeFrame: baseline, 4 weeks, 12 weeks
measure: Change of SF-12 Health Survey Questionnaire from baseline to 12 weeks
timeFrame: baseline, 4 weeks, 12 weeks
measure: Change of Waddell Disability Index from baseline to 12 weeks
timeFrame: baseline, 4 weeks, 12 weeks
measure: Change of hearth rate variability (HRV) expressed as coherent ratio from baseline to 4 weeks
timeFrame: baseline, 4 weeks
Other outcomes:
Locations:
city: Rome
country: Italy
facility: Umberto I Hospital
Study officials:
affiliation: Umberto I Hospital, University "Sapienza" of Rome
name: Vincenzo Maria Saraceni
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04366180: Evaluation of the Probiotic Lactobacillus Coryniformis K8 on COVID-19 Prevention in Healthcare Workers
Official title: Multicentric Study to Assess the Effect of Consumption of Lactobacillus Coryniformis K8 on Healthcare Personnel Exposed to COVID-19
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Covid-19
Keywords: Covid-19
Prevention
Healthcare workers
Lead sponsor: Biosearch S.A.
Sponsor class: INDUSTRY
First posted: 2020-04-28
Enrollment: 314
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The aim of the present study is to evaluate the effects of Lactobacillus coryniformis K8 consumption on the incidence and severity of Covid-19 in health workers exposed to the virus. This is a preventive study


Eligibility criteria: Inclusion Criteria:

1. Persons over 20 years of age.
2. Active healthcare personnel, who attend patients with COVID-19 disease, including all professional categories, medicine, nursing and warders.
3. Ability to complete surveys.
4. Signature of informed consent

Exclusion Criteria:

1. Person with positive test of COVID-19 confirmed by PCR test or serology
2. Person with concomitant pathology HIV, transplant, active oncology or other type of active immunosuppression
3. Pregnant women or women with intention to become pregnant in the next 2 months.

Primary outcomes:
measure: Incidence of SARS CoV-2 infection in healthcare workers
timeFrame: 8 weeks
Secondary outcomes:
measure: Incidence of hospital admissions caused by SARS-CoV-2 infection
timeFrame: 8 weeks
measure: Incidence of ICU admissions caused by SARS-CoV-2 infection
timeFrame: 8 weeks
measure: Incidence of pneumonia caused by SARS-CoV-2 infection
timeFrame: 8 weeks
measure: Incidence of oxygen support requirement caused by SARS-CoV-2 infection
timeFrame: 8 weeks
measure: Incidence of gastrointestinal symptoms caused by SARS-CoV-2 infection
timeFrame: 8 weeks
measure: Days with body's temperature > 37.5 ºC
timeFrame: 8 weeks
measure: Days with cough
timeFrame: 8 weeks
measure: Days with fatigue
timeFrame: 8 weeks
measure: Medical treatment
timeFrame: 8 weeks
Other outcomes:
Locations:
city: Granada
country: Spain
facility: Raquel Rodriguez Blanque
Study officials:
References: